Invention Grant
- Patent Title: CDK2 inhibitors
-
Application No.: US17235846Application Date: 2021-04-20
-
Publication No.: US11773082B2Publication Date: 2023-10-03
- Inventor: Douglas Carl Behenna , Kevin Daniel Freeman-Cook , Robert Louis Hoffman , Asako Nagata , Sacha Ninkovic , Scott Channing Sutton
- Applicant: Pfizer Inc.
- Applicant Address: US NY New York
- Assignee: PFIZER INC.
- Current Assignee: PFIZER INC.
- Current Assignee Address: US NY New York
- Agent Alexey G. Kuznetsov; Bryan C. Zielinski
- The original application number of the division: US16774786 2020.01.28
- Main IPC: C07D403/12
- IPC: C07D403/12 ; A61P35/00 ; C07D413/12

Abstract:
This invention relates to compounds of Formula (I)
and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
Public/Granted literature
- US20210269425A1 CDK2 INHIBITORS Public/Granted day:2021-09-02
Information query